Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
The Ministry of Health, Labor and Welfare (MHLW) will promote Fumi Yamamoto to councilor in charge of pharmaceuticals at the Health Minister’s Secretariat, effective January 1, making her the first women to assume the highest rank for officers with pharmacy-related…
To read the full story
Related Article
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Councilor Mori, MHLW's Top Pharmacy Officer, to Bow Out at Year-End
December 19, 2019
REGULATORY
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…